pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
NOVO · news · pharmadog
← back to NOVO
News mentioning NOVO
165
stories
May 6, 26
STAT+: Pharmalittle: We’re reading about a PhRMA ad campaign aimed at 340B, sales of Novo’s obesity pill, and more
stat
May 6, 26
Novo Nordisk's Q1 in four words: Pills, pricing, payments and pressure
endpoints
May 5, 26
STAT+: Pharma’s reputation among patient groups rose last year, but concerns remain over access and pricing
stat
May 5, 26
STAT+: Pharmalittle: We’re reading about RFK Jr. targeting antidepressants, J&J pushing an IBD drug, and more
stat
May 4, 26
STAT+: French regulator fines Novo and Lilly over weight loss ad campaigns
stat
May 1, 26
Amgen launches late-stage obesity trial in patients who switch from rival drugs
endpoints
May 1, 26
STAT+: Pharmalittle: We’re reading about obesity drugs and a compounding list, an AstraZeneca setback, and more
stat
May 1, 26
Two biotechs raise a combined $556M in latest spurt of IPOs
biopharma dive
Apr 30, 26
STAT+: FDA wants to exclude weight loss drugs from a compounding list
stat
Apr 30, 26
Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch
biopharma dive
Apr 30, 26
Updated: Early sales of Lilly’s obesity pill appear to trail Novo’s
endpoints
Apr 28, 26
Boehringer dual-acting obesity shot hits mark in Phase 3 trial
biopharma dive
Apr 28, 26
Coultreon banks $125M to support testing of former Galapagos immune drug
biopharma dive
Apr 28, 26
Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
biopharma dive
Apr 28, 26
Boehringer, Zealand’s obesity shot looks as good as Novo's Wegovy, but weaker than Lilly's Zepbound
endpoints
← prev
page 6 of 6
next →
